BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26293331)

  • 1. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
    Goodday RH
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptives and osteonecrosis of the jaw.
    Yamashita J; McCauley LK
    J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bisphosphonate and osteonecrosis of the jaw.].
    Taguchi A
    Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonate-related osteonecrosis of the jaw].
    Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
    Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
    Larsson Wexell C; Kjellman A; Akre O
    Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of osteoclast modifiers on the oral cavity: a review for prescribers.
    Epstein MS; Epstein JB; Ephros HD
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):337-41. PubMed ID: 22871978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preserving the oral health of patients on antiresorptive drugs].
    Tilotta F; Folliguet M; Radoï L
    Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate-related osteonecrosis of the jaw].
    Franken AA; van Blijderveen NJ; Witjes MJ; Netelenbos CJ
    Ned Tijdschr Geneeskd; 2011; 155():A3077. PubMed ID: 21486510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
    Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.